Sodium–glucose co-transporter 2 (SGLT-2) inhibitors are a class of orally administered agents originally designed for the management of type 2 diabetes mellitus (T2DM) [1]. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.